Accessibility Menu
Olema Pharmaceuticals logo

Olema Pharmaceuticals

(NASDAQ) OLMA

Current Price$10.29
Market Cap$900.55M
Since IPO (2020)-78%
5 Year-63%
1 Year+145%
1 Month-32%

Olema Pharmaceuticals Financials at a Glance

Market Cap

$900.55M

Revenue (TTM)

$0.00

Net Income (TTM)

-$185.15M

EPS (TTM)

-$2.03

P/E Ratio

-5.09

Dividend

$0.00

Beta (Volatility)

1.46 (Average)

Price

$10.29

Volume

2,519,669.051

Open

$10.60

Previous Close

$10.31

Daily Range

$10.02 - $10.75

52-Week Range

$3.89 - $36.26

Estimated Earnings Date

Aug 10, 2026

OLMA: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Olema Pharmaceuticals

Industry

Biotechnology

Employees

131

CEO

Sean P. Bohen, MD, PhD

Headquarters

San Francisco, CA 94107, US

OLMA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-43%

Return on Capital

-42%

Return on Assets

-35%

Earnings Yield

-19.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$900.55M

Shares Outstanding

87.35M

Volume

2.52M

Avg. Volume

1.52M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$178.70M

EBITDA

-$178.21M

Operating Cash Flow

-$146.72M

Capital Expenditure

$0.00

Free Cash Flow

-$146.72M

Cash & ST Invst.

$505.44M

Total Debt

$1.19M

Olema Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$119.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$900.55M

N/A

Market Cap/Employee

$9.38M

N/A

Employees

96

N/A

Net Income

-$53.09M

-74.7%

EBITDA

-$57.87M

-66.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$504.39M

+28.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$956.00K

-6.7%

Return on Assets

-34.89%

N/A

Return on Invested Capital

-41.74%

N/A

Free Cash Flow

-$45.99M

-4.6%

Operating Cash Flow

-$45.99M

-4.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRVSCorvus Pharmaceuticals, Inc.
$11.12-5.12%
LXRXLexicon Pharmaceuticals, Inc.
$1.91+0.53%
ABSIAbsci Corporation
$6.40-12.81%
VTYXVentyx Biosciences, Inc.
$14.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About OLMA

What is the current price of Olema Pharmaceuticals?

Olema Pharmaceuticals is trading at $10.31 per share.

What is the 52-week range for Olema Pharmaceuticals?

Over the past 52 weeks, Olema Pharmaceuticals has traded between $3.89 and $36.26.

How much debt does Olema Pharmaceuticals have?

As of the most recent reporting period, Olema Pharmaceuticals reported total debt of $3.96M.

How much cash does Olema Pharmaceuticals have on hand?

Olema Pharmaceuticals reported $52.55M in cash and cash equivalents in its most recent financial results.

What is Olema Pharmaceuticals’s dividend yield?

Olema Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.